Spyre Therapeutics ( (SYRE) ) just unveiled an announcement.
Spyre Therapeutics, a clinical-stage biotech firm, is advancing its pipeline with a novel monoclonal antibody, SPY003, targeting IL-23 for treating inflammatory bowel disease (IBD). With promising preclinical results and extended half-life, SPY003 could offer a more convenient dosing schedule. The company plans to start first-in-human trials by early 2025, potentially enhancing efficacy and convenience of IBD therapies compared to current standards.
Learn more about SYRE stock on TipRanks’ Stock Analysis page.